Trial of tocilizumab for bleeding stroke to prevent later strokes
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if a drug called tocilizumab (TYENNE) can reduce the risk of delayed strokes after a bleeding stroke from a ruptured aneurysm. It is for adults who had a specific type of brain bleed and need a drain to remove fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had a bleeding stroke from a burst aneurysm within the last 24 hours, confirmed by a scan.
- You have a drain placed in your brain or spine (or plan to have one put in).
- If you could become pregnant, a pregnancy test must be negative, and you agree to use non-hormonal birth control or not have sex during the study and for 2 months after the last dose.
- If you are a man with a partner who could become pregnant, you agree to use a condom or not have sex during the study and for 2 months after the last dose, and not donate sperm.
- You are able to attend follow-up visits and give consent (or have someone who can).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a medicine called tirofiban (which helps prevent blood clots) can improve recovery after a brain aneurysm rupture. It is for people who have had their aneurysm treated with a coil and are at risk of a delayed stroke.
This trial tests whether the drug cilostazol can prevent delayed brain damage in people who have had bleeding from a brain aneurysm. It is for adults who had their aneurysm treated within 72 hours and are in moderate to serious condition.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This trial tests a drug called C1-inhibitor (a protein that calms inflammation) given shortly after a bleeding stroke caused by an aneurysm. The goal is to see if it can reduce brain damage and improve recovery.
This trial tests whether the drug tocilizumab (which blocks a protein called interleukin-6) can help prevent further strokes in people who have had a stroke or mini-stroke due to a narrowed artery inside the skull. If you are eligible, you would receive either tocilizumab or a placebo to see if it reduces your risk of another stroke.
This trial studies whether tranexamic acid (a medicine that helps blood clot) can improve outcomes after a spontaneous (not caused by injury) brain bleed. It is designed for adults who arrive soon after stroke symptoms start and meet several safety and timing requirements.
Hear when a new Aneurysmal Subarachnoid Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.